LQDA insider trading
HealthcareLiquidia Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Liquidia Corp
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Company website: www.liquidia.com
LQDA insider activity at a glance
FilingIQ has scored 647 insider transactions for LQDA since Jul 30, 2018. The most recent filing in our index is dated May 12, 2026.
Across the full history, 52 open-market purchases
and 242 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LQDA insider trades is 56.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest LQDA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding LQDA
Frequently asked
- How many insider trades does FilingIQ track for LQDA?
- FilingIQ tracks 647 Form 4 insider transactions for LQDA (Liquidia Corp), covering filings from Jul 30, 2018 onwards. 115 of those were filed in the last 90 days.
- Are LQDA insiders net buyers or net sellers?
- Across the full Form 4 history for LQDA, 52 transactions (8%) were open-market purchases and 242 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LQDA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LQDA in?
- Liquidia Corp (LQDA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.00B.
Methodology & sources
Every LQDA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.